Cingulate (CING) Competitors $4.24 +0.06 (+1.44%) Closing price 04/17/2025 03:57 PM EasternExtended Trading$4.21 -0.03 (-0.71%) As of 04/17/2025 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CING vs. BDRX, ADAP, ASRT, IOBT, CABA, INCR, PYRGF, VIRI, AVTX, and ANROShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Biodexa Pharmaceuticals (BDRX), Adaptimmune Therapeutics (ADAP), Assertio (ASRT), IO Biotech (IOBT), Cabaletta Bio (CABA), InterCure (INCR), PyroGenesis Canada (PYRGF), Virios Therapeutics (VIRI), Avalo Therapeutics (AVTX), and Alto Neuroscience (ANRO). These companies are all part of the "pharmaceutical products" industry. Cingulate vs. Biodexa Pharmaceuticals Adaptimmune Therapeutics Assertio IO Biotech Cabaletta Bio InterCure PyroGenesis Canada Virios Therapeutics Avalo Therapeutics Alto Neuroscience Biodexa Pharmaceuticals (NASDAQ:BDRX) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment. Do insiders & institutionals have more ownership in BDRX or CING? 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Comparatively, 17.1% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better earnings & valuation, BDRX or CING? Biodexa Pharmaceuticals has higher revenue and earnings than Cingulate. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiodexa Pharmaceuticals$83K629.61-$7.66MN/AN/ACingulateN/AN/A-$23.53M-$14.64-0.29 Does the MarketBeat Community prefer BDRX or CING? Cingulate received 10 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 78.57% of users gave Cingulate an outperform vote. CompanyUnderperformOutperformBiodexa PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesCingulateOutperform Votes1178.57% Underperform Votes321.43% Do analysts rate BDRX or CING? Cingulate has a consensus target price of $16.00, indicating a potential upside of 277.36%. Given Cingulate's stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cingulate 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media prefer BDRX or CING? In the previous week, Biodexa Pharmaceuticals and Biodexa Pharmaceuticals both had 1 articles in the media. Biodexa Pharmaceuticals' average media sentiment score of 0.00 beat Cingulate's score of -1.00 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Biodexa Pharmaceuticals Neutral Cingulate Negative Is BDRX or CING more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets Biodexa PharmaceuticalsN/A N/A N/A Cingulate N/A -570.20%-236.15% Which has more risk and volatility, BDRX or CING? Biodexa Pharmaceuticals has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.87, indicating that its stock price is 187% less volatile than the S&P 500. SummaryBiodexa Pharmaceuticals and Cingulate tied by winning 7 of the 14 factors compared between the two stocks. Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulatePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.98M$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.29%P/E Ratio-0.296.9521.9417.82Price / SalesN/A231.03380.9597.68Price / CashN/A65.6738.2634.64Price / Book-0.065.936.453.98Net Income-$23.53M$143.22M$3.22B$247.81M1 Month Performance11.58%-13.56%-9.76%-7.91%1 Year Performance382.31%-8.89%11.49%1.53% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate2.0906 of 5 stars$4.24+1.4%$16.00+277.4%+381.8%$15.98MN/A-0.2920Short Interest ↑Negative NewsBDRXBiodexa Pharmaceuticals0.2212 of 5 stars$1.65-6.8%N/AN/A$60.30M$83,000.000.0020News CoverageGap DownADAPAdaptimmune Therapeutics2.8732 of 5 stars$0.23+5.2%$1.83+682.4%-73.5%$60.17M$178.03M-1.06490Gap UpASRTAssertio1.9407 of 5 stars$0.62+0.3%$2.75+342.3%-19.0%$59.55M$124.96M-0.8520IOBTIO Biotech2.8443 of 5 stars$0.90+4.8%$9.33+939.3%-41.5%$59.16MN/A-0.6630Short Interest ↑Gap UpCABACabaletta Bio1.9138 of 5 stars$1.16-5.7%$21.00+1,710.3%-92.1%$58.86MN/A-0.5450INCRInterCure0.5095 of 5 stars$1.28+3.6%N/A-46.9%$58.33M$272.67M0.00350Short Interest ↑News CoveragePYRGFPyroGenesis CanadaN/A$0.31-1.3%N/A-5.3%$58.25M$9.14M-5.2090VIRIVirios TherapeuticsN/A$2.99+1.7%$3.00+0.3%+863.2%$57.58MN/A-11.075News CoverageAVTXAvalo Therapeutics3.2928 of 5 stars$5.38+9.8%$33.00+513.4%-63.3%$57.42M$441,000.000.0040Short Interest ↑ANROAlto Neuroscience1.7108 of 5 stars$2.11-0.9%$15.40+629.9%-83.4%$57.12MN/A-0.83N/AGap Up Related Companies and Tools Related Companies Biodexa Pharmaceuticals Competitors Adaptimmune Therapeutics Competitors Assertio Competitors IO Biotech Competitors Cabaletta Bio Competitors InterCure Competitors PyroGenesis Canada Competitors Virios Therapeutics Competitors Avalo Therapeutics Competitors Alto Neuroscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CING) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
